Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Current Alzheimer Research

• Publication date

  2017-10-31

• Fields of study

  Medicine, Materials Science, Engineering

• Identifiers
  DOI 10.2174/1567205014666170508121031PMID 28482786PMCID PMC5878045
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diamondoid Molecules

  2017cited by this paper
• The detection of β-amyloid plaques in an Alzheimer's disease rat model with DDNP-SPIO.

  2015cited by this paper
• Emerging advances in cancer nanotheranostics with graphene nanocomposites: opportunities and challenges.

  2015cited by this paper
• World Alzheimer report 2014: Dementia and risk reduction

  2015cited by this paper
• Rivastigmine-loaded in situ gelling nanostructured lipid carriers for nose to brain delivery

  2015cited by this paper
• A nanotechnological approach to the management of Alzheimer disease and type 2 diabetes.

  2014influential reference
• The molecular mechanism of fullerene-inhibited aggregation of Alzheimer's β-amyloid peptide fragment.

  2014cited by this paper
• Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer's disease mice.

  2014cited by this paper
• Multimodal nanoprobes to target cerebrovascular amyloid in Alzheimer's disease brain.

  2014cited by this paper
• Engineering theranostic nanovehicles capable of targeting cerebrovascular amyloid deposits.

  2014cited by this paper
• Interactions of a water-soluble fullerene derivative with amyloid-β protofibrils: dynamics, binding mechanism, and the resulting salt-bridge disruption.

  2014cited by this paper
• Influence of water-soluble derivatives of [60]fullerene on therapeutically important targets related to neurodegenerative diseases

  2014cited by this paper
• Nanomedicine Based Drug Targeting in Alzheimer’s Disease: High Impact of Small Carter

  2014cited by this paper
• Resveratrol: review on therapeutic potential and recent advances in drug delivery

  2014cited by this paper
• Epigallocatechin-3-gallate (EGCG)-stabilized selenium nanoparticles coated with Tet-1 peptide to reduce amyloid-β aggregation and cytotoxicity.

  2014cited by this paper
• Transformation of curcumin from food additive to multifunctional medicine: nanotechnology bridging the gap.

  2014cited by this paper
• Role of nanomedicines in delivery of anti-acetylcholinesterase compounds to the brain in Alzheimer's disease.

  2014influential reference
• Role of Graphene Nano-Composites in Cancer Therapy: Theranostic Applications, Metabolic Fate and Toxicity Issues.

  2014cited by this paper
• Towards Non-Invasive Diagnostic Imaging of Early-Stage Alzheimer’s Disease

  2014influential reference
• Neuroprotective Effects of Resveratrol Against Aβ Administration in Rats are Improved by Lipid-Core Nanocapsules

  2013cited by this paper
• Glutamate system, amyloid ß peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology.

  2013cited by this paper
• Antibody-conjugated, dual-modal, near-infrared fluorescent iron oxide nanoparticles for antiamyloidgenic activity and specific detection of amyloid-β fibrils

  2013cited by this paper
• Benefits of combined cholinesterase inhibitor and memantine treatment in moderate–severe Alzheimer's disease

  2013cited by this paper
• Curcumin-conjugated nanoliposomes with high affinity for Aβ deposits: possible applications to Alzheimer disease.

  2013cited by this paper
• Memantine-sulfur containing antioxidant conjugates as potential prodrugs to improve the treatment of Alzheimer's disease.

  2013cited by this paper
• Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer’s disease

  2013cited by this paper
• SPION-Enhanced Magnetic Resonance Imaging of Alzheimer's Disease Plaques in AβPP/PS-1 Transgenic Mouse Brain

  2013cited by this paper
• Theranostics: are we there yet?

  2013cited by this paper
• Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers.

  2013cited by this paper
• Effect of viologen-phosphorus dendrimers on acetylcholinesterase and butyrylcholinesterase activities.

  2013cited by this paper
• Small-Molecule Theranostic Probes: A Promising Future in Neurodegenerative Diseases

  2013cited by this paper
• Cerium oxide caged metal chelator: anti-aggregation and anti-oxidation integrated H2O2-responsive controlled drug release for potential Alzheimer's disease treatment

  2013cited by this paper
• Resveratrol-Loaded Polymeric Nanoparticles: Validation of an HPLC-PDA Method to Determine the Drug Entrapment and Evaluation of Its Antioxidant Activity

  2013cited by this paper
• Highly Stabilized Curcumin Nanoparticles Tested in an In Vitro Blood–Brain Barrier Model and in Alzheimer’s Disease Tg2576 Mice

  2013cited by this paper
• Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor.

  2012cited by this paper
• Neuronal Uptake and Neuroprotective Effect of Curcumin-Loaded PLGA Nanoparticles on the Human SK-N-SH Cell Line

  2012cited by this paper
• Phosphorus dendrimers affect Alzheimer's (Aβ1-28) peptide and MAP-Tau protein aggregation.

  2012influential reference
• Surface-Engineered Nanoliposomes by Chelating Ligands for Modulating the Neurotoxicity Associated with β-Amyloid Aggregates of Alzheimer’s disease

  2012cited by this paper
• Curcumin Loaded-PLGA Nanoparticles Conjugated with Tet-1 Peptide for Potential Use in Alzheimer's Disease

  2012cited by this paper
• Synthesis, characterization and potential applications of multifunctional PEO-PPOPEO- magnetic drug delivery system.

  2012cited by this paper
• Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting.

  2012cited by this paper
• Negatively charged gold nanoparticles inhibit Alzheimer's amyloid-β fibrillization, induce fibril dissociation, and mitigate neurotoxicity.

  2012cited by this paper
• Where, when, and in what form does sporadic Alzheimer's disease begin?

  2012cited by this paper
• Epidemiology of Alzheimer disease.

  2012cited by this paper
• Antibody-conjugated PEGylated cerium oxide nanoparticles for specific targeting of Aβ aggregates modulate neuronal survival pathways.

  2012cited by this paper
• Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes.

  2012cited by this paper
• Nanotechnological advances for the delivery of CNS therapeutics.

  2012cited by this paper
• Gold nanoparticles in theranostic oncology: current state-of-the-art

  2012cited by this paper
• Cancer targeted metallic nanoparticle: targeting overview, recent advancement and toxicity concern.

  2011cited by this paper
• Nanotechnology for Alzheimer’s disease detection and treatment

  2011cited by this paper
• Detection of amyloid plaques targeted by USPIO-Aβ1-42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging

  2011cited by this paper
• Epidemiology of Alzheimer disease

  2011cited by this paper
• Bionanotechnologies for treatment and diagnosis of Alzheimer's disease.

  2011influential reference
• Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues.

  2011cited by this paper
• Development and evaluation of polymer nanoparticles for oral delivery of estradiol to rat brain in a model of Alzheimer's pathology.

  2011cited by this paper
• Alzheimer's disease.

  2011cited by this paper
• Reversible blood-brain barrier disruption by repeated transcranial focused ultrasound allows enhanced extravasation.

  2011cited by this paper
• Microbubble-Size Dependence of Focused Ultrasound-Induced Blood–Brain Barrier Opening in Mice In Vivo

  2010cited by this paper
• Neuroprotective mechanism conferred by 17beta-estradiol on the biochemical basis of Alzheimer's disease.

  2010cited by this paper
• Targeting the brain--surmounting or bypassing the blood-brain barrier.

  2010cited by this paper
• Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease.

  2010cited by this paper
• ApoE3 mediated poly(butyl) cyanoacrylate nanoparticles containing curcumin: study of enhanced activity of curcumin against beta amyloid induced cytotoxicity using in vitro cell culture model.

  2010cited by this paper
• Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering.

  2010cited by this paper
• Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies.

  2010cited by this paper
• In vivo labelling of hippocampal β‐amyloid in triple‐transgenic mice with a fluorescent acetylcholinesterase inhibitor released from nanoparticles

  2010cited by this paper
• Various drug delivery approaches to the central nervous system

  2010cited by this paper
• Polycation cytotoxicity: a delicate matter for nucleic acid therapy-focus on polyethylenimine

  2010cited by this paper
• Effects of rivastigmine on common symptomatology of Alzheimer’s disease (EXPLORE)

  2010cited by this paper
• Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead.

  2010influential reference
• Pharmacological and toxicological target organelles and safe use of single-walled carbon nanotubes as drug carriers in treating Alzheimer disease.

  2010cited by this paper
• Nanoparticulate Radiolabelled Quinolines Detect Amyloid Plaques in Mouse Models of Alzheimer's Disease

  2010cited by this paper
• Clinical Nanomedicine: Nanomedical approaches in Alzheimer’s disease

  2010cited by this paper
• Alzheimer's disease.

  2010cited by this paper
• Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease.

  2010cited by this paper
• Synthesis of fluorescent-maghemite nanoparticles as multimodal imaging agents for amyloid-beta fibrils detection and removal by a magnetic field.

  2009cited by this paper
• Cerium Oxide Nanoparticles Trigger Neuronal Survival in a Human Alzheimer Disease Model By Modulating BDNF Pathway

  2009influential reference
• Nanoparticle-chelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease.

  2009cited by this paper
• Resveratrol-loaded polymeric micelles protect cells from Abeta-induced oxidative stress.

  2009cited by this paper
• Nanoparticles can cause DNA damage across a cellular barrier.

  2009cited by this paper
• Ultrasensitive and highly selective detection of Alzheimer's disease biomarker using two-photon Rayleigh scattering properties of gold nanoparticle.

  2009influential reference
• Development of semagacestat (LY450139), a functional γ-secretase inhibitor, for the treatment of Alzheimer's disease

  2009cited by this paper
• Protective actions of sex steroid hormones in Alzheimer's disease.

  2009cited by this paper
• Real-Time Imaging and Quantification of Amyloid-β Peptide Aggregates by Novel Quantum-Dot Nanoprobes

  2009cited by this paper
• The binding of pullulan modified cholesteryl nanogels to Abeta oligomers and their suppression of cytotoxicity.

  2009cited by this paper
• Ultra-sensitive immunosensor for beta-amyloid (1-42) using scanning tunneling microscopy-based electrical detection.

  2009cited by this paper
• Ultrasound for drug and gene delivery to the brain.

  2008cited by this paper
• Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles.

  2008cited by this paper
• Bioconjugated quantum rods as targeted probes for efficient transmigration across an in vitro blood-brain barrier.

  2008cited by this paper
• Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice.

  2008cited by this paper
• Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease.

  2008cited by this paper
• Nanoparticle assisted magnetic resonance imaging of the early reversible stages of amyloid beta self-assembly.

  2008cited by this paper
• Efficient Inhibition of the Alzheimer's Disease β-Secretase by Membrane Targeting

  2008cited by this paper
• Drug Development Based on the Metals Hypothesis of Alzheimer's Disease

  2008influential reference
• Progress in Drug Delivery to the Central Nervous System by the Prodrug Approach

  2008cited by this paper
• Results from a phase I safety trial of hAADC gene therapy for Parkinson disease

  2008cited by this paper
• Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo.

  2007influential reference
• Branched KLVFF Tetramers Strongly Potentiate Inhibition of β‐Amyloid Aggregation

  2007cited by this paper
• Attenuation of beta-amyloid-induced toxicity by sialic-acid-conjugated dendrimers: role of sialic acid attachment.

  2007cited by this paper
• Nanoparticles aggravate heat stress induced cognitive deficits, blood-brain barrier disruption, edema formation and brain pathology.

  2007cited by this paper
• Improved bioavailability of orally administered mifepristone from PLGA nanoparticles.

  2007influential reference

• Targeting Alzheimer’s disease pathology: influence of nano-based drug delivery systems loaded with a combination of herbal and synthetic drugs

  2025cites this paper
• From Flower to Medicine: Green-Synthesized Silver Nanoparticles as Promising Antibacterial Agents

  2025cites this paper
• Nanoscale drug formulations for the treatment of Alzheimer's disease progression

  2025cites this paper
• Quercetin loaded-magnetic zeolite nano-composite material and evaluate its anti-cancer effect

  2025cites this paper
• Therapeutic and clinical potential of thiolutin microneedles on Alzheimer's disease mitigation.

  2025cites this paper
• Research Progress of Eye Movement Analyses and its Detection Algorithms in Alzheimer's Disease.

  2024cites this paper
• Amylovis-201 is a new dual-target ligand, acting as an anti-amyloidogenic compound and a potent agonist of the σ1 chaperone protein

  2024cites this paper
• A critical review on the role of nanotheranostics mediated approaches for targeting β amyloid in Alzheimer’s

  2023influential citation
• Virus-Based Biological Systems as Next-Generation Carriers for the Therapy of Central Nervous System Diseases

  2023cites this paper
• Small-molecule theranostics in Alzheimer's disease.

  2023cites this paper
• Current and Future Nano-Carrier-Based Approaches in the Treatment of Alzheimer’s Disease

  2023cites this paper
• Nature's Toolbox Against Tau Aggregation: An Updated Review of Current Research.

  2023cites this paper
• Multifunctional Nanocarriers for Alzheimer’s Disease: Befriending the Barriers

  2023cites this paper
• The relationship between Alzheimer disease and thyroiditis: A two-sample Mendelian randomization study

  2023cites this paper
• Potential Neuroprotective Strategies using Smart Drug Delivery Systems for Alzheimer's Disease.

  2023cites this paper
• A Promising Approach: Magnetic Nanosystems for Alzheimer’s Disease Theranostics

  2023cites this paper
• Role of BDNF signaling in the neuroprotective and memory-enhancing effects of flavonoids in Alzheimer's Disease.

  2023cites this paper
• A review on nanotechnological perspective of "the amyloid cascade hypothesis" for neurodegenerative diseases.

  2023cites this paper
• Self-Fluorescent Lone Tryptophan Nanoparticles as Theranostic Agents Against Alzheimer's Disease.

  2022cites this paper
• Nanotechnology for the diagnosis and treatment of Alzheimer's disease: A bibliometric analysis

  2022cites this paper
• Functionalization strategies of polymeric nanoparticles for drug delivery in Alzheimer’s disease: Current trends and future perspectives

  2022cites this paper
• Optical Nanosensor for Intracellular and Intracranial Detection of Amyloid-Beta.

  2022cites this paper
• Progress of Nanotechnology-Based Detection and Treatment of Alzheimer’s Disease Biomarkers

  2022cites this paper
• Liposomes: Production Methods and Application in Alzheimer's Disease.

  2021cites this paper
• Obstructions in Nanoparticles Conveyance, Nano-Drug Retention, and EPR Effect in Cancer Therapies

  2021cites this paper
• Plasmonic Nanoparticles as Optical Sensing Probes for the Detection of Alzheimer’s Disease

  2021cites this paper
• Advancement in design of nanostructured lipid carriers for cancer targeting and theranostic application.

  2021cites this paper
• The Potential Benefits of Nanotechnology in Treating Alzheimer's Disease

  2021cites this paper
• Artificial Intelligence in Nanotechnology: Recent Trends, Challenges and Future Perspectives

  2021cites this paper
• Strategic approaches to target the enzymes using natural compounds for the management of Alzheimer's disease: A review.

  2021cites this paper
• Nanomedicines and phytochemicals targeting Alzheimer’s disease

  2021cites this paper
• Diagnostic and theranostic intranasal nanointerventions for brain diseases

  2021cites this paper
• Alzheimer Hastalığı Tedavisindeki Güncel Yaklaşımlar

  2021cites this paper
• Drug Delivery Systems and Strategies to Overcome the Barriers of Brain.

  2021cites this paper
• Recent Advances in Nanotechnology: A Novel Therapeutic System for the Treatment of Alzheimer's Disease.

  2020cites this paper
• The structure and function of α, β and γ-Secretase as therapeutic target enzymes into the development of Alzheimer's disease: A review.

  2020cites this paper
• Nanomedicine against Alzheimer's and Parkinson's disease.

  2020cites this paper
• Nanomaterials for the treatment and diagnosis of Alzheimer's disease: An overview

  2020cites this paper
• Advances in nanomedicines for diagnosis of central nervous system disorders.

  2020cites this paper
• Molecular Targets and Nanoparticulate Systems Designed for the Improved Therapeutic Intervention in Glioblastoma Multiforme

  2020cites this paper
• Nanotechnology in Early Detection and Treatment of Amyloidosis

  2020cites this paper
• Current trends, achievements, and prospects of smart nanodevices in the global pharma market

  2020cites this paper
• Fluorescent Dopamine-tryptophan nanocomposites as dual imaging and anti-aggregation agents: New generation of amyloid theranostics with trimeric effects.

  2020cites this paper
• Innovative Therapies and Nanomedicine Applications for the Treatment of Alzheimer’s Disease: A State-of-the-Art (2017–2020)

  2020cites this paper
• Nanostructured Lipid Carriers (Nlcs): Nose-to-Brain Delivery and Theranostic Application.

  2020cites this paper
• Functional Bionanomaterials: From Biomolecules to Nanoparticles

  2020cites this paper
• Nanotechnology in the Discovery of New Antimicrobial Drugs: Is a New Scientific Revolution Possible?

  2020cites this paper
• Galantamine Delivery for Alzheimer’s Disease

  2020cites this paper
• Preclinical Evaluation of Antimicrobial Nanodrugs

  2020cites this paper
• Sustainable Agriculture Reviews 43: Pharmaceutical Technology for Natural Products Delivery Vol. 1 Fundamentals and Applications

  2020cites this paper
• DNA Microsystems for Biodiagnosis

  2020cites this paper
• Recent Advances in Nanotherapeutic Interventions for the Treatment of Alzheimer's Disease.

  2020cites this paper
• Recent Progress of Nanomedicine in the Treatment of Central Nervous System Diseases

  2020cites this paper
• Homing of Super Paramagnetic Iron Oxide Nanoparticles (SPIONs) Labeled Adipose-Derived Stem Cells by Magnetic Attraction in a Rat Model of Parkinson’s Disease

  2020cites this paper
• Potential application of liposomal nanodevices for non-cancer diseases: an update on design, characterization and biopharmaceutical evaluation.

  2020cites this paper
• Upconversion Nanomaterials for Near-infrared Light-Mediated Theranostics

  2019cites this paper
• Nanowired delivery of cerebrolysin with neprilysin and p-Tau antibodies induces superior neuroprotection in Alzheimer's disease.

  2019cites this paper
• Nanoparticle technology and stem cell therapy team up against neurodegenerative disorders.

  2019cites this paper
• Glucose‐linked sub‐50‐nm unimer polyion complex‐assembled gold nanoparticles for targeted siRNA delivery to glucose transporter 1‐overexpressing breast cancer stem‐like cells

  2019cites this paper
• Neurotheranostics as personalized medicines.

  2019cites this paper
• Potential of Tribological Properties of Metal Nanomaterials in Biomedical Applications.

  2019cites this paper
• Alzheimer's Disease Targeted Nano-Based Drug Delivery Systems.

  2019cites this paper
• Advancements in nanotherapeutics for Alzheimer’s disease: current perspectives

  2019cites this paper
• Rendimiento cognitivo en envejecimiento: efecto del sueño, del ejercicio y de la TMS en Octodon degus

  2017cites this paper
• Editorial: Alzheimer's Disease: From Molecular Mechanisms to Psychobiological Perspectives.

  2017cites this paper
• Herbal-based nanosystems: A novel drug-delivery treatment procedure against neurodegenerative disorders

  year unknowncites this paper
• Nanoparticles of Herbal Extracts in Treatment of Neurodegenerative Disorders

  year unknowncites this paper